Reimer D L, Kong S, Monck M, Wyles J, Tam P, Wasan E K, Bally M B
British Columbia Cancer Agency, Division of Medical Oncology, Section of Advanced Therapeutics, Vancouver, British Columbia, Canada.
J Pharmacol Exp Ther. 1999 May;289(2):807-15.
The transfer of plasmid expression vectors to cells is essential for transfection after administration of lipid-based DNA formulations (lipoplexes). A murine i.p. B16/BL6 tumor model was used to characterize DNA delivery, liposomal lipid delivery, and gene transfer after regional (i.p.) administration of free plasmid DNA and DNA lipoplexes. DNA lipoplexes were prepared using cationic dioleoyldimethylammonium chloride/dioleoylphosphatidylethanolamine (50:50 mol ratio) liposomes mixed with plasmid DNA (1 microgram DNA/10 nmol lipid). The plasmid used contained the chloramphenicol acetyltransferase gene and chloramphenicol acetyltransferase expression (mU/g tumor) was measured to estimate transfection efficiency. Tumor-associated DNA and liposomal lipid levels were measured to estimate the efficiency of lipid-mediated DNA delivery to tumors. Plasmid DNA delivery was estimated using [3H]-labeled plasmid as a tracer, dot blot analysis, and/or Southern analysis. Liposomal lipid delivery was estimated using [14C]-dioleoylphosphatidylethanolamine as a liposomal lipid marker. Gene expression in the B16/BL6 tumors was highly variable, with values ranging from greater than 2,000 mU/g tumor to less than 100 mU/g tumor. There was a tendency to observe enhanced transfection in small (<250 mg) tumors. Approximately 18% of the injected dose of DNA was associated with these small tumors 2 h after i.p. administration. Southern analysis of extracted tumor DNA indicated that plasmid DNA associated with tumors was intact 24 h after administration. DNA and associated liposomal lipid are efficiently bound to tumors after regional administration; however, it is unclear whether delivery is sufficient to abet internalization and appropriate subcellular localization of the expression vector.
对于基于脂质的DNA制剂(脂质体复合物)给药后的转染而言,将质粒表达载体导入细胞至关重要。使用小鼠腹腔注射B16/BL6肿瘤模型来表征游离质粒DNA和DNA脂质体复合物经区域(腹腔)给药后的DNA递送、脂质体脂质递送和基因转移情况。DNA脂质体复合物是用阳离子二油酰二甲基氯化铵/二油酰磷脂酰乙醇胺(摩尔比50:50)脂质体与质粒DNA(1微克DNA/10纳摩尔脂质)混合制备而成。所用质粒含有氯霉素乙酰转移酶基因,并通过测量氯霉素乙酰转移酶表达(每克肿瘤的毫微单位)来评估转染效率。测量肿瘤相关的DNA和脂质体脂质水平,以评估脂质介导的DNA递送至肿瘤的效率。使用[3H]标记的质粒作为示踪剂、斑点印迹分析和/或Southern分析来评估质粒DNA递送情况。使用[14C] - 二油酰磷脂酰乙醇胺作为脂质体脂质标记物来评估脂质体脂质递送情况。B16/BL6肿瘤中的基因表达变化很大,值的范围从每克肿瘤大于2000毫微单位到小于100毫微单位。在小(<250毫克)肿瘤中观察到转染增强的趋势。腹腔给药后2小时,约18%的注射剂量的DNA与这些小肿瘤相关。对提取的肿瘤DNA进行Southern分析表明,给药后24小时与肿瘤相关的质粒DNA是完整的。区域给药后,DNA和相关的脂质体脂质有效地结合到肿瘤上;然而,尚不清楚递送是否足以促进表达载体的内化和适当的亚细胞定位。